185 related articles for article (PubMed ID: 17062962)
1. Arrhythmogenic effects of arsenic trioxide in patients with acute promyelocytic leukemia and an electrophysiological study in isolated guinea pig papillary muscles.
Yamazaki K; Terada H; Satoh H; Naito K; Takeshita A; Uehara A; Katoh H; Ohnishi K; Hayashi H
Circ J; 2006 Nov; 70(11):1407-14. PubMed ID: 17062962
[TBL] [Abstract][Full Text] [Related]
2. Effect of arsenic trioxide on QT interval in patients with advanced malignancies.
Barbey JT; Pezzullo JC; Soignet SL
J Clin Oncol; 2003 Oct; 21(19):3609-15. PubMed ID: 14512391
[TBL] [Abstract][Full Text] [Related]
3. Prolongation of cardiac repolarization by arsenic trioxide.
Chiang CE; Luk HN; Wang TM; Ding PY
Blood; 2002 Sep; 100(6):2249-52. PubMed ID: 12200393
[TBL] [Abstract][Full Text] [Related]
4. Choline-modulated arsenic trioxide-induced prolongation of cardiac repolarization in Guinea pig.
Sun HL; Chu WF; Dong DL; Liu Y; Bai YL; Wang XH; Zhou J; Yang BF
Basic Clin Pharmacol Toxicol; 2006 Apr; 98(4):381-8. PubMed ID: 16623862
[TBL] [Abstract][Full Text] [Related]
5. The effect of arsenic trioxide on QT interval prolongation during APL therapy.
Zhou J; Meng R; Li X; Lu C; Fan S; Yang B
Chin Med J (Engl); 2003 Nov; 116(11):1764-6. PubMed ID: 14642155
[TBL] [Abstract][Full Text] [Related]
6. Ventricular repolarization dynamics in arsenic trioxide treatment of acute promyelocytic leukemia.
Sun Y; Wang L; Que Y; Zhu H; Yang X; Li D
Int J Cardiol; 2020 May; 306():163-167. PubMed ID: 31761398
[TBL] [Abstract][Full Text] [Related]
7. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Takeshita A; Sugiyama S; Satoh H; Terada H; Ohno R
Ann Intern Med; 2000 Dec; 133(11):881-5. PubMed ID: 11103058
[TBL] [Abstract][Full Text] [Related]
8. Direct effects of arsenic trioxide on action potentials in isolated cardiac tissues: importance of the choice of species, type of cardiac tissue and perfusion time.
Lu HR; Vlaminckx E; Cools F; Gallacher DJ
J Pharmacol Toxicol Methods; 2012 Sep; 66(2):135-44. PubMed ID: 22445855
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide.
Litzow MR
Expert Opin Pharmacother; 2008 Jul; 9(10):1773-85. PubMed ID: 18570609
[TBL] [Abstract][Full Text] [Related]
10. Arsenic trioxide - An old drug rediscovered.
Emadi A; Gore SD
Blood Rev; 2010; 24(4-5):191-9. PubMed ID: 20471733
[TBL] [Abstract][Full Text] [Related]
11. [Clinical and experimental study of cardiac effects of conventional dosage arsenic trioxide in APL patients].
Zhou J; Meng R; Liu Y; Wang W; Li BX; Yang BF
Zhonghua Xue Ye Xue Za Zhi; 2004 Jan; 25(1):31-4. PubMed ID: 14990074
[TBL] [Abstract][Full Text] [Related]
12. Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia.
Barbey JT; Soignet S
Ann Intern Med; 2001 Nov; 135(9):842-3. PubMed ID: 11694116
[No Abstract] [Full Text] [Related]
13. Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.
Huan SY; Yang CH; Chen YC
Leuk Lymphoma; 2000 Jul; 38(3-4):283-93. PubMed ID: 10830735
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity in African-American patients treated with arsenic trioxide for acute promyelocytic leukemia.
Patel SP; Garcia-Manero G; Ferrajoli A; Faderl S; Verstovek S; Kantarjian H; Estey E
Leuk Res; 2006 Mar; 30(3):362-3. PubMed ID: 16168477
[No Abstract] [Full Text] [Related]
15. Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.
Unnikrishnan D; Dutcher JP; Varshneya N; Lucariello R; Api M; Garl S; Wiernik PH; Chiaramida S
Blood; 2001 Mar; 97(5):1514-6. PubMed ID: 11222403
[TBL] [Abstract][Full Text] [Related]
16. Risk/benefit profile of arsenic trioxide.
Rust DM; Soignet SL
Oncologist; 2001; 6 Suppl 2():29-32. PubMed ID: 11331438
[TBL] [Abstract][Full Text] [Related]
17. Arsenic trioxide therapy for relapsed or refractory Japanese patients with acute promyelocytic leukemia: need for careful electrocardiogram monitoring.
Ohnishi K; Yoshida H; Shigeno K; Nakamura S; Fujisawa S; Naito K; Shinjo K; Fujita Y; Matsui H; Sahara N; Takeshita A; Satoh H; Terada H; Ohno R
Leukemia; 2002 Apr; 16(4):617-22. PubMed ID: 11960341
[TBL] [Abstract][Full Text] [Related]
18. [Study on cardiac toxicity in acute promyelocyte leukemia treatment of arsenic trioxide intravenous infusion in general dose].
Zhou J; Meng R; Wang W; Lü CF; Yang BF
Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):785-8. PubMed ID: 14636467
[TBL] [Abstract][Full Text] [Related]
19. Monomorphic ventricular tachycardia caused by arsenic trioxide therapy for acute promyelocytic leukaemia.
Ducas RA; Seftel MD; Ducas J; Seifer C
J R Coll Physicians Edinb; 2011 Jun; 41(2):117-8. PubMed ID: 21677914
[TBL] [Abstract][Full Text] [Related]
20. Arsenic trioxide as first-line treatment for acute promyelocytic leukemia.
Leu L; Mohassel L
Am J Health Syst Pharm; 2009 Nov; 66(21):1913-8. PubMed ID: 19850784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
